Please login to the form below

Not currently logged in
Email:
Password:

Retrophin

This page shows the latest Retrophin news and features for those working in and with pharma, biotech and healthcare.

Retrophin rockets away as rare disease trial hits targets

Retrophin rockets away as rare disease trial hits targets

Retrophin rockets away as rare disease trial hits targets. Sparsentan has potential to become a blockbuster FSG drug, according to analysts. ... What a difference a year makes. Under pressure in 2015, US firm Retrophin now has a positive trial in hand

Latest news

More from news
Approximately 4 fully matching, plus 5 partially matching documents found.

Latest Intelligence

  • Pharma deals in August 2015 Pharma deals in August 2015

    More recently Retrophin sold its PRV to Sanofi for $245m, so it looks as though values are definitely on the rise!

  • Pharma deals in May 2015 Pharma deals in May 2015

    Sanofi purchased the paediatric PRV from Retrophin for the total consideration of $245m ($150m on closure with two subsequent payments in 2016 and 2017 of $47.7m). ... 300. Retrophin/ Sanofi. Acquisition of priority review voucher [PRV]. For Cholbam

  • Pharma deals during February 2014 Pharma deals during February 2014

    Recently public, Retrophin has acquired Manchester Pharmaceuticals, a speciality pharmaceutical company that focuses on treatments for rare diseases. ... Retrophin is paying a total of $62.5m, including an upfront of $29.5m, plus royalties based on

  • Deal Watch table for February 2014 Deal Watch table for February 2014

    Licence termination. DiaPep277 for type 1 diabetes patients. 72. Manchester Pharmaceuticals / Retrophin.

More from intelligence
Approximately 0 fully matching, plus 4 partially matching documents found.

Latest appointments

  • Amryt Pharma appoints new regulatory affairs head Amryt Pharma appoints new regulatory affairs head

    Amryt Pharma appoints new regulatory affairs head. Derval O’Carroll joins the rare disease-focused biopharma from Retrophin. ... Prior to joining Amryt, she served as senior director of regulatory affairs for rare disease group Retrophin.

More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Create Health

A healthcare marketing agency that shares your passion for making things better. Our clients with solve real health problems every...

Latest intelligence

patients
Retaining reader value in plain language summaries of clinical studies
Balancing the risk of misinterpretation with the public’s ability to understand simplified plain-language summaries...
Can we talk about the ego-bias and chemicals influencing your target audience’s behaviour?
Over the Summer, the Page & Page team became fascinated by two books on this very subject. Two books from one author, Dean Burnett, an eminent neuroscientist, lecturing at Cardiff...
Paris
Making Europe a leader in bioscience: boosting trust and opening minds
A vision of Paris as Europe’s leading hub for life sciences innovation...

Infographics